BIND Biosciences, Inc. Secures $8.7 Million

Clinical stage biopharmaceutical company BIND Biosciences Inc. has received $8.7 million in equity financing, federal documents show. Cambridge, Mass.-based BIND, which develops nanoparticle technology that concentrates a drug right at the site of cancer cells (which minimizes exposure to the healthy tissue and decreases side effects), received the funding from a total of 20 investors. In October 2011, BIND received a $47.35 million financing from RUSANO, a billion dollar investment fund focused on nanotechnology, existing investors and new investors. Co-founded in 2007 by Omid Farokhzad, associate professor at Harvard Medical School and physician-scientist at Brigham and Women’s Hospital, and serial entrepreneur Robert Langer, BIND also has its own proprietary drug candidates. The company’s lead compound, BIND-014, is in Phase 1 clinical testing.